( October 27, 2026, 8:49 AM EDT) -- NEW ORLEANS — A Fifth Circuit U.S. Court of Appeals panel vacated the class certification order in a securities fraud class action against a biopharmaceutical company and certain of its executives, finding that the lower court did not properly assess evidence of market inefficiency....